Veriluce is  a drug development company  currently involved in the computational design and development of novel small molecule  therapeutics. Veriluce is currently focused on GPCR chemokine receptor antagonists with the aim to modulate the tumour immune micro-environment to inhibit tumour growth and metastasis. VeriLuce is also exploring ophthalmic diseases as another potential  therapeutic target. The expected mode of action of each of these molecules is via antagonistic/blocking activity of 2 specific chemokine receptors.

VeriLuce Therapeutics Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total